How Methotrexate Reduces Efficacy of Other Drugs
Methotrexate (MTX), a folate antagonist used for rheumatoid arthritis, cancer, and psoriasis, inhibits dihydrofolate reductase, disrupting DNA synthesis and purine/pyrimidine production. This mechanism enables MTX to decrease the efficacy of co-administered drugs by competing for metabolic pathways, inducing efflux transporters like ABCG2, or altering absorption.[1]
Common Drug Interactions Lowering Efficacy
- Antibiotics: MTX reduces absorption and efficacy of penicillins (e.g., amoxicillin) and tetracyclines by forming inactive complexes in the gut or competing for renal secretion. Levels of both drugs drop, impairing infection control.[1][2]
- NSAIDs: Ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) decrease MTX clearance via organic anion transporter inhibition, but MTX reciprocally lowers NSAID efficacy by enhancing their renal excretion.[2]
- Probenecid: Used for gout, probenecid blocks MTX tubular secretion, raising MTX toxicity while MTX diminishes probenecid's uricosuric effect.[1]
- Sulfasalazine: MTX inhibits sulfasalazine's anti-inflammatory action in rheumatoid arthritis by competing for folate-dependent pathways.[2]
Mechanisms Behind Efficacy Loss
MTX upregulates multidrug resistance proteins (e.g., MRP2/ABCC2), pumping out other substrates like etoposide or doxorubicin from cells, reducing their anticancer effects. It also competes with drugs like trimethoprim for dihydrofolate reductase, blocking their antimicrobial activity.[1][3] In high-dose regimens, MTX-induced renal impairment further lowers clearance of renally excreted drugs like cisplatin.
Cancer Therapy Impacts
In chemotherapy, low-dose MTX weakens efficacy of methotrexate combinations like CHOP (with cyclophosphamide, doxorubicin). High-dose MTX effluxes vinca alkaloids (vincristine) and taxanes, requiring dose adjustments.[3] Pediatric ALL protocols note MTX reduces asparaginase efficacy by altering asparagine depletion.
Timing and Management to Preserve Efficacy
Interactions peak with weekly low-dose MTX (7.5-25 mg); separate administration by 24-48 hours. Folic acid supplements (1-5 mg/day) mitigate MTX effects without fully restoring partner drug levels. Monitor via AUC calculations for narrow therapeutic index drugs.[2]
[1]: Drugs.com - Methotrexate Interactions
[2]: Lexicomp - Methotrexate Monograph
[3]: PubMed - Methotrexate Drug Interactions Review